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We have previously reported expression of vascular
endothelial growth factor (VEGF)-A and -C in glomeru-
lar podocytes and actions of VEGF-A on glomerular en-
dothelial cells (GEnC) that express VEGF receptor-2
(VEGFR-2). Here we define VEGFR-3 expression in GEnC
and investigate the effects of the ligand VEGF-C. Renal
cortex and cultured GEnC were examined by micros-
copy, and both cell and glomerular lysates were as-
sessed by Western blotting. VEGF-C effects on trans-
endothelial electrical resistance and albumin flux
across GEnC monolayers were measured. The effects of
VEGF-C156S, a VEGFR-3-specific agonist, andVEGF-Awere
also studied. VEGF-C effects on intracellular calcium
([Ca2]i) were measured using a fluorescence technique,
receptor phosphorylation was examined by immunopre-
cipitation assays, and phosphorylation of myosin light
chain-2 and VE-cadherin was assessed by blotting with
phospho-specific antibodies. GEnC expressed VEGFR-3 in
tissue sections and culture, and VEGF-C increased trans-
endothelial electrical resistance in a dose-dependentman-
nerwith amaximal effect at 120minutes of 6.8whereas
VEGF-C156S had no effect. VEGF-C reduced labeled albu-
min flux by 32.8%. VEGF-C and VEGF-A increased [Ca2]i
by 15% and 39%, respectively. VEGF-C phosphorylated
VEGFR-2 but not VEGFR-3, myosin light chain-2, or VE-
cadherin. VEGF-C increased GEnC monolayer integrity
and increased [Ca2]i, whichmay be related to VEGF-C-S
particular receptor binding and phosphorylation induc-
tion characteristics. These observations suggest that
podocytes direct GEnC behavior through both VEGF-C
and VEGF-A. (Am J Pathol 2008, 173:938–948; DOI:
10.2353/ajpath.2008.070416)
Normal glomerular filtration depends on the combined
properties of the three layers of the glomerular capillary
wall; glomerular endothelial cells (GEnC), glomerular
basement membrane, and glomerular epithelial cells or
podocytes. Each of these layers has unique features
essential for their function. GEnC, unlike the majority of
endothelial cells, are highly fenestrated suggesting the
action of particular local chemical or physical factors that
induce this phenotype. Vascular endothelial growth fac-
tor (VEGF or VEGF-A) is a strong candidate molecule
because it can be shown to induce fenestrations both in
vivo and in vitro.1,2 VEGF-A is the prototypical VEGF family
member and has powerful actions on endothelial cells
including survival, proliferation, chemotaxis (all important
in angiogenesis), and induction of permeability.3 These
actions on endothelial cells are predominantly mediated
through VEGF receptor 2 (VEGFR-2).4,5 VEGF-A also ac-
tivates VEGFR-1 but not VEGFR-3. VEGF-C has many
similar functions to VEGF-A, also acting via VEGFR-2,
and can stimulate the proliferation and migration of en-
dothelial cells and increase vascular permeability in
vivo, but with potency four to five times less than VEGF-
A.6,7 VEGF-C also has angiogenic properties8,9 and
can induce fenestration formation10 but is a more potent
inducer of lymphangiogenesis.11,12 Actions on lymphatic
endothelium occur primarily via VEGFR-3.5,11,13,14 VEGF-C
does not activate VEGFR-1.
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VEGFR-3 has an essential role in the development of
the embryonic cardiovascular system before the emer-
gence of the lymphatic vessels.15 Thereafter it is widely
expressed in vascular and lymphatic endothelium during
embryonic development13,16 and is also essential for nor-
mal lymphangiogenesis.17 After organogenesis it be-
comes primarily restricted to lymphatic endothelium13,16
but has been detected in some vascular endothelia in
adult tissues notably in discontinuous endothelia of bone
marrow and splenic sinusoids, some fenestrated endo-
thelia, including that of endocrine organs,18,19 and in
capillaries of various organs.20
We and others have shown that podocytes express
VEGF-A and angiopoietin 1 (ang1, a member of another
family of endothelium-regulating factors21) whereas the
adjacent GEnC express the cognate receptors VEGFR-1,
VEGFR-2 and Tie2.22,23 These observations suggest a
relationship analogous to that seen between mural cells
and endothelial cells in other vessels, where podocytes
may influence GEnC phenotype and hence their contri-
bution to the unique permeability characteristics of the
glomerular capillary wall. Indeed VEGF-A and ang1 both
have effects on barrier properties of GEnC in vitro.24
Further evidence in support of such an interaction is
accumulating. Both experimental administration of neu-
tralizing antibodies to VEGF-A and podocyte-specific re-
duction in VEGF-A production cause GEnC abnormalities
including swelling, vacuolation, and detachment along
with proteinuria.25–27
We have recently described the expression of VEGF-C
by podocytes, both in vivo and in vitro, and have demon-
strated autocrine actions on podocytes.28 Observations
by other groups showing that GEnC express VEGFR-3 in
vivo18,19 suggest that VEGF-C, along with VEGF-A and
ang1, might also be a mediator of the podocyte’s ability
to direct GEnC phenotype. We have now confirmed the
expression of VEGFR-3 in isolated glomeruli and GEnC in
vivo and in culture and have examined the actions of
VEGF-C on GEnC, demonstrating effects, some of which
are opposite to those seen with VEGF-A. Our results point
more toward involvement of VEGFR-2, rather than
VEGFR-3, in these effects on GEnC. These observations
lend credence to a physiological role for VEGF-C in
podocyte-GEnC interactions.
Materials and Methods
Nephrectomy Tissue
Human renal tissue was obtained, with consent and un-
der ethical approval from the Southmead Hospital local
research ethics committee, from patients undergoing ne-
phrectomy for renal carcinoma. Within 30 minutes after
nephrectomy, samples of cortex from the normal pole
were taken for extraction of glomeruli by sieving.
Cell Culture
Human GEnC were obtained at passage 3 from the Ap-
plied Cell Biology Research Institute (Kirkland, WA) and
were used for experiments up to passage 8. We have
previously characterized these cells in detail including
their expression of intercellular adhesion molecules, for-
mation of monolayers in culture and responses to control
mediators in barrier property assays.24 Human lung mi-
crovascular endothelial cell (LMVEC, derived from adult
lung tissue; Clonetics Corp., San Diego, CA) were ob-
tained at passage 3 and used for experiments up to pas-
sage 7. Human lymphatic microvascular endothelial cells
(LEC, derived from adult dermal tissue; Clonetics) were
obtained at passage 3 and used up to passage 5. All
endothelial cells were cultured in EGM2-MV (endothelial
growth medium 2, microvascular; Cambrex, Wokingham,
UK), made up from EBM2 (endothelial basal medium 2,
Cambrex) and fetal calf serum (5%), antimicrobial agents,
and growth factors as supplied, excepting VEGF-A.
Primary and Secondary Antibodies
A goat polyclonal antibody to VEGFR-3 (AF349; R&D
Systems, Minneapolis, MN) was used for confocal mi-
croscopy, Western blotting, and immunoprecipitation
studies. A second VEGFR-3 antibody (mouse monoclonal
anti-human VEGFR-3, 9D9, was a kind gift from Prof. K.
Alitalo, Helsinki, Finland) was used for immunoelectron
microscopy and for Western blotting and immunoprecipi-
tation studies. For confocal microscopy an Alexa Fluor
633-conjugated secondary was used (Molecular Probes,
Invitrogen, Paisley, UK). Two VEGFR-2 antibodies were
used, one for immunoprecipitation (rabbit polyclonal, sc-
504; Santa Cruz Biotechnology, Santa Cruz, CA) and one
for Western blotting (mouse monoclonal antibody, 05-
554; Upstate, Millipore, Billerica, MA). An anti-phospho-
tyrosine mouse monoclonal antibody (4G10, Cell Signal-
ing Technology, Danvers, MA) was also used for Western
blotting of immunoprecipitated proteins. Antibodies to
phospho-VE cadherin (Tyr658, AB1955; Chemicon, Milli-
pore) phospho-myosin light chain (MLC)-2 (Ser19,
3671s; Cell Signaling Technology), total VE-cadherin and
total MLC-2 (F-8 and FL-172, respectively, both Santa
Cruz Biotechnology) were used to examine downstream
effector pathways by Western blotting.
Confocal and Immunoelectron Microscopy
GEnC grown to confluence on glass coverslips were
fixed in 4% fresh paraformaldehyde in phosphate-buff-
ered saline (PBS), permeabilized in 0.2% Triton X-100 in
PBS and incubated with 0.1% sodium borohydride. Cells
were then incubated with primary antibody in 1% bovine
serum albumin (BSA) and secondary antibody in PBS. In
the control samples, primary antibody was replaced with
nonimmune immunoglobulin of the same species and
concentration. Cells were co-stained with 5 mol/L 4,6-
diamidino-2-phenylindole before mounting in MOWIOL
4-88 (Calbiochem, San Diego, CA) containing 0.6% 1,4-
diazabicyclo-(2.2.2)octane (Dabco; Sigma Chemical Co.,
St Louis, MO) as an anti-photobleaching agent. Confocal
microscopy was performed using an AOBS SP confocal
laser-scanning system (Leica, Wetzlar, Germany) at-
tached to a Leica DM IRE2 inverted epifluorescence
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microscope. Immunoelectron microscopy, using an indi-
rect immunogold procedure, was performed on Lowicryl
ultra-thin human renal cortex sections, as described
previously.29
Western Blotting
GEnC were lysed in Laemmli sample buffer and solubi-
lized protein concentrations were determined (bicincho-
ninic acid assay; Pierce Chemical Co., Rockford, IL).
Lysates of HMVECs, vascular smooth muscle cells
(VSMC) (a gift from Dr. C. Shanahan, University of Cam-
bridge, Cambridge, UK), LEC, and sieved glomeruli were
used as controls. Protein samples were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) under reducing conditions and were
blotted onto nitrocellulose membranes. The membranes
were air-dried and blocked in 5% fat-free milk before
incubation with antibodies to VEGFR-3 (as above) and
actin (Sigma) to confirm loading of comparable amounts
of protein in each lane. After incubation with horseradish
peroxidase-conjugated secondary antibodies (Santa
Cruz), bands were detected using the ECL chemilumi-
nescence system (Amersham Biotech Ltd., Bucks, UK).
Effect of VEGF-C on trans-Endothelial Electrical
Resistance (TEER) of GEnC Monolayers
Polycarbonate supports (0.4-m pore size, 0.5 cm2 sur-
face area) in tissue culture inserts (1 cm diameter; Nalge
Nunc International, Rochester, NY) were seeded with
GEnC at 100,000 cells/cm2. After 5 days the medium was
replaced with serum-free medium (EBM2) and 1 hour
later the TEER of cell monolayers was measured as de-
scribed previously using an Endohm 12 electrode cham-
ber and an EVOMx voltohmeter (World Precision Instru-
ments, Sarasota, FL).24 Tissue culture inserts were
placed sequentially in the chamber and the resistance
recorded after 10 seconds. VEGF-C (R&D Systems), or
control, was then added to give a final concentration of 1
or 10 nmol/L and TEER was remeasured at 60 and 120
minutes. Some inserts were also treated with 1 nmol/L
VEGF-A (R&D Systems) as a control because the effect of
VEGF-A in this assay is already established.24 In other
experiments, VEGF-C was replaced with the mutant
VEGF-C, VEGF-C156S (R&D Systems), a selective agonist
of VEGFR-3 that does not bind VEGFR-2.5,7 VEGF-C156S
was used at concentrations of 1, 10, and 50 nmol/L.
Effect of VEGF-C on Protein Passage across
GEnC Monolayers
Trans-monolayer permeability to macromolecules was
assessed by measuring passage of fluorescein isothio-
cyanate-labeled bovine serum albumin (FITC-BSA,
Sigma) across the monolayer essentially as described
previously.24 GEnC monolayers were prepared in tissue
culture inserts and after 5 days the medium was replaced
with EBM2 as above. After 1 hour VEGF-C was added to
give a final concentration of 10 nmol/L. Simultaneously
FITC-BSA was added to medium within the inserts to give
a final concentration of 500 g/ml and unlabeled BSA
was added to the medium in the well to the same con-
centration. At 1, 2, and 3 hours 100-l aliquots were
removed and replaced with 100 l of serum-free medium
(SFM) containing unlabeled BSA. The fluorescence emis-
sion of the aliquots at 520 nm after excitation at 490 nm
was measured on a Packard Instruments FluoroCount
fluorospectro-photometer (PerkinElmer Life Sciences,
Wellesley, MA) and the concentration of FITC-BSA cal-
culated by reference to a set of standard dilutions.
Effects of VEGF-C on [Ca2]i
GEnC grown to confluence on 22-mm diameter glass
coverslips were incubated with the high-affinity, ratiomet-
ric, and UV light-excitable intracellular calcium indicator
Fura 2-AM (10 mol/L, Molecular Probes) for 90 minutes
in EBM2 at 37°C, and each coverslip in turn was then
placed in a coverslip holder. The holder was mounted on
a rig consisting of an inverted fluorescence microscope
(DM IRB, Leica) equipped with a UV source (Cairn In-
struments, Faversham, UK) with filters for excitation at
340 and 380 nm. Fast switching was achieved using a
rotary filter wheel at 50 Hz and a spectrophotometer for
photometric measurement (Cairn Instruments). The spec-
trophotometer received emitted light via a 400-nm di-
chroic filter and a 510- to 530-nm barrier filter in front of
the photometer. A Powerlab data acquisition unit and
Chart 5 software (both from AD Instruments, Colorado
Springs, CO) were used for analysis and graphic display.
Experiments were conducted in Krebs-Ringer phosphate
buffer (150 mmol/L NaCl, 6 mmol/L KCl, 1 mmol/L MgCl2,
10 mmol/L D-glucose, and 10 mmol/L HEPES and CaCl2
1.5 mmol/L). Baseline recordings were established and
Krebs-Ringer buffer was changed with that containing 10
nmol/L human recombinant VEGF-C (final concentration),
10 nmol/L VEGF-C156S, or 0.1% BSA vehicle and left to
record for 20 minutes. One nmol/L VEGF-A was used in
similar experiments as a positive control for the assay
because it has been shown to increase [Ca2]i in human
umbilical vein endothelial cells (HUVEC).30 To ensure
that [Ca2]i was effectively measured, 10 mol/L iono-
mycin was added to stimulate Ca2 entry into the cells.
One mmol/L of manganese chloride (MnCl2), in the con-
tinued presence of 10 mol/L ionomycin, was then used
to quench the Fura 2-AM to determine the background
(Ca2-independent) fluorescence signal. Emission fluo-
rescent measurements (If) were taken four times a sec-
ond. The ratio of the If measured during 340-nm excita-
tion to that during 380-nm excitation (Rnorm), proportional to
the calcium concentration, was calculated from Rnorm 
R
exp
/Rmin where Rexp (If340 B340)/(If380 B380). If340 is
the If measured during excitation at 340 nm, If380 is the If
measured during excitation at 380 nm, and B340 and B380
are the background If values measured during excita-
tions at 340 and 380 nm, respectively (measured as the If
after Mn2 quenching). Rmin is the in vitro ratio for zero
[Ca2]i. The use of this ratio facilitates the detection of
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small changes in [Ca2]i, which are independent of the
Fura 2-AM loading. The Rnorm was plotted against time
and the peak to baseline ratios of Rnorm were calculated
as a measure of the maximal effect on [Ca2]i, and
compared between treatment and control groups. The
rate of rise of [Ca2]i was also plotted as dRnorm/dt and
compared between VEGF-A- and VEGF-C-treated cells.
VEGF Receptor Phosphorylation Assays and
Immunoprecipitation
To determine the effect of exogenous VEGF-C on
VEGFR-2 and VEGFR-3 phosphorylation in GEnC, cells
were serum-starved for 4 hours and then treated with 10
nmol/L VEGF-C for 2, 5 ,7, 10, 30, or 90 minutes or with
vehicle control. LEC were used as a positive control for
VEGFR-3 phosphorylation. Effects of VEGF-C on
VEGFR-2 phosphorylation were compared with those of
VEGF-A (1 nmol/L, 2 minutes). Cells were then lysed,
cleared, and protein was quantified as described above.
Lysate from each sample was incubated with 4 g of
primary antibody (anti-VEGFR-2 or anti-VEGFR-3, 9D9)
per 1000 g of total protein overnight at 4°C with gentle
agitation. Sixty l of washed A/G agarose beads per 500
l of lysate was then added to each of the samples and
left to incubate for at least 4 hours, rocking at 4°C. Sam-
ples were then centrifuged for 3 minutes at 13,000 rpm at
4°C, and the supernatant was removed and retained and
the precipitate was washed three times with lysis buffer.
Equal quantities of supernatant and total lysate, or the
entire precipitate of each protein sample lysate were
mixed with 3 SDS loading buffer (100 mmol/L Tris, pH
6.8, 4% SDS, 20% glycerol, 10% -mercaptoethanol, and
0.2% bromophenol blue) and boiled for 5 minutes. The
precipitate samples were vortexed, then centrifuged for a
further 30 seconds at 13,000 rpm. All samples were run
on a 7.5% SDS-PAGE gel at 100 V and were then trans-
ferred to nitrocellulose membranes for 120 minutes at 60
V. The membrane was probed with an anti-phosphoty-
rosine antibody, then stripped and reprobed for total
VEGFR-2 or VEGFR-3 (AF349). The membranes were
blocked in 5% fat-free milk (or 3% BSA/PBS-Tween for
the anti-phospho-tyrosine antibody) before incubation
with antibodies described above. After incubation with
horseradish peroxidase-conjugated secondary antibod-
ies, bands were detected using the ECL chemilumines-
cence system or the SuperSignal West Femto maximum
sensitivity substrate (Pierce).
Analysis of Downstream Effector Molecules
To further investigate the differential effects of VEGF-A and
VEGF-C on barrier properties, we examined phosphoryla-
tion of the downstream effector molecules VE-cadherin and
MLC-2. GEnC were serum-starved for 4 hours, then stimu-
lated with 1 nmol/L VEGF-A or 10 nmol/L VEGF-C for 10
(MLC-2) or 30 minutes (VE-cadherin) before lysis and anal-
ysis by Western blotting. Resulting membranes were immu-
noblotted for phospho-VE-cadherin or phospho-MLC-2
then stripped and reprobed for total protein.
Statistical Analyses
Statistical analyses were performed using GraphPad
Prism (GraphPad Prism Software Inc., San Diego, CA),
SPSS 11.0 (SPSS, Chicago, IL), or Excel. Comparisons
were made by Student’s t-test or analysis of variance.
Results shown are representative of, or a combination of,
at least three separate experiments as indicated in the
figure legends. Results are presented as mean  SE.
Results
VEGFR-3 Expression
Immunoelectron microscopy showed strong expression
of VEGFR-3 on GEnC in human renal cortex using a
second VEGFR-3 antibody (Figure 1). Minimal podocyte
staining was seen with this antibody (9D9) and tech-
nique. Western blotting of sieved glomeruli and Western
blotting and confocal microscopy of cultured GEnC con-
firmed the presence of VEGFR-3 in sieved glomeruli and
in cultured GEnC (Figure 2). The 130-kDa proteolytically
cleaved and 170-kDa unglycosylated forms31 were
clearly identified in GEnC. The larger glycosylated form
(195 kDa) was more faintly detected. LMVEC expressed
high levels of VEGFR-3, consistent with evidence that
primary culture microvascular endothelial cells contain a
Figure 1. Glomerular VEGFR-3 expression by immunoelectron microscopy
on human renal cortex tissue sections using a mouse monoclonal antibody
(9D9). Gold particles can be clearly seen labeling the glomerular endothe-
lium indicating VEGFR-3 expression (arrows). The bottom image includes
a grazing section of the glomerular endothelium with fenestrations visible en
face. Minimal podocyte labeling was seen. Scale bars  100 nm.
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mixture of lymphatic and vascular endothelial cells.5 (This
is not for the case for GEnC because glomeruli do not
contain lymphatics.) Similarly, LEC expressed high levels
of VEGFR-3 with bands corresponding to those in GEnC
and LMVEC in Western blots using both AF349 and 9D9
antibodies.
Effects of VEGF-C on GEnC Monolayer Barrier
Properties
VEGF-C caused an increase in TEER of GEnC monolay-
ers and this effect was dose-dependent with a maximal
effect of 10 nmol/L VEGF-C at 120 minutes of 6.8  0.5
(Figure 3). Importantly the direction of this effect is oppo-
site to that seen with VEGF-A, which, as we have reported
previously causes a reduction in GEnC monolayer
TEER.24 In contrast, VEGF-C156S in concentrations up to
50 nmol/L had no effect on TEER of GEnC monolayers
(not shown). Consistent with the increase in TEER,
VEGF-C also reduced passage of labeled albumin
across GEnC monolayers throughout 3 hours by 32.8%
(Figure 4).
Effects of VEGF-A and VEGF-C on [Ca2]i
VEGF-A (1 nmol/L) caused an increase in Rnorm of 1.39
0.02 (P  0.001) indicating an increase in [Ca2]i in
GEnC (Figure 5). This is consistent with previous obser-
vations in HUVEC.30 VEGF-C (10 nmol/L) also increased
Rnorm, although to a lesser degree, by 1.15  0.03 (P 
0.01). VEGF-C156S (10 nmol/L), which activates only
VEGFR-3, did not increase [Ca2]i (Rnorm 1.02  0.01).
Analysis of the rate of Ca2 flux (dRnorm/dt) revealed
no significant difference between VEGF-A and VEGF-C
treatment (Figure 6). There was considerable variability in
dRnorm/dt induced by VEGF-A that may have obscured a
significant effect. However the profile of the response to
the two mediators was different with the time to peak rate
of Ca2 flux occurring significantly later with VEGF-C
(VEGF-A induced peak flux: 122.4  13.0 seconds,
VEGF-C induced peak flux: 415.7  118.4 seconds, P 
0.05).
Effects of VEGF-C on VEGF Receptor
Phosphorylation
VEGF-A induced the phosphorylation of VEGFR-2 at 2
minutes (Figure 7). VEGF-C-induced phosphorylation of
VEGFR-2 was not detectable at 2, 5, or 7 minutes (not
shown) but was apparent at 10 minutes, maximal at 30
minutes (although to a lesser extent than with VEGF-A),
and diminished by 90 minutes (Figure 8). This is consis-
tent with previous observations of VEGFR-2 phosphory-
lation by VEGF-D, which induced lesser phosphorylation
Figure 2. A: Confocal microscopy showing expression of VEGFR-3 by hu-
man GEnC cultured on coverslips. B: Western blotting analyses of protein
extracted from GEnC, human LMVEC, vascular smooth muscle cells (VSMC),
glomeruli sieved from normal renal cortex (Gloms), and LEC using goat
polyclonal (AF349) and mouse monoclonal (9D9) antibodies. LMVEC and
LEC are used as positive controls, VSMC as negative controls. The blots
confirm expression of VEGFR-3 in GEnC (albeit at a lower level than in
LMVEC and LEC) and in human glomeruli. The 130-kDa proteolytically
cleaved and 170-kDa unglycosylated forms are clearly identified in GEnC.
The larger glycosylated form (195 kDa) is more faintly detected. Actin bands
confirm the loading of comparable amounts of protein. Numbers on left and
right indicate expected molecular weight of bands and molecular weights of
marker proteins, respectively.
Figure 3. The effects of VEGF-C (1 or 10 nmol/L) and VEGF-A (1 nmol/L) on
TEER of GEnC monolayers over time. Bars show mean  SE normalized to
control 0, n  6, P  0.0001 overall by repeated measures (rm) analysis of
variance. Post hoc comparisons (Bonferroni), 1 and 10 nmol/L VEGF-C
versus control both P  0.01. Ten nmol/L VEGF-C increased TEER by a
maximum of 6.8  0.5 at 120 minutes. Results shown are representative of
five separate experiments.
Figure 4. The effect of VEGF-C (10 nmol/L) on passage of FITC-BSA across
GEnC monolayers throughout time. Bars show mean  SE, n  5 to 8, P 
0.05 by repeated measures analysis of variance. VEGF-C reduced the amount
of FITC-BSA passing through GEnC monolayers throughout 3 hours by
32.8%. Results shown are representative of three separate experiments.
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and peaked at 30 minutes, in contrast to VEGF-A that
induced a peak effect before 5 minutes.30 We could not
demonstrate the phosphorylation of VEGFR-3 by VEGF-C
or VEGF-C156S in GEnC after 5 minutes of exposure
(Figure 8) or any other time point tested (not shown).
Phosphorylation of VEGFR-3 in LEC by both molecules
confirmed the ability of the assay to detect VEGFR-3
phosphorylation as well as the activity of the VEGF-
C156S mutant. However, it is likely that the lower levels of
VEGFR-3 expression in GEnC, compared with LEC, ren-
dered phosphorylation more difficult to detect and we do
not exclude the possibility that some phosphorylation has
occurred, below the sensitivity of the assay.
Analysis of Downstream Effector Molecules
VEGF-A induced phosphorylation of VE-cadherin and
showed a trend toward increased phosphorylation of
MLC-2 (Figure 9) as anticipated from studies in other
endothelial cells. However, despite phosphorylation of
VEGFR-2, VEGF-C did not induce phosphorylation of ei-
ther molecule.
Discussion
Expression of VEGFR-3 in Glomeruli and
Cultured GEnC
Demonstration of the expression of VEGFR-3 in glomeruli
is consistent with previous reports.18,19 Using immuno-
electron microscopy we have shown that this expression
is localized to the glomerular endothelium. Because
VEGFR-3 is expressed only by some blood vessel endo-
thelial cells, in particular in fenestrated capillaries, it is
likely that VEGFR-3 is important in some, as yet undefined
way, in maintenance of this endothelial cell phenotype. In
addition to its physiological role in lymphatics, VEGFR-3
Figure 5. The effects of VEGF-A (1 nmol/L) and
VEGF-C (10 nmol/L) on the change in [Ca2]i in
GEnC incubated in Krebs-Ringer phosphate
buffer. GEnC were serum-starved and loaded with
fura-2-AM. VEGF-A, VEGF-C, or C156S was then
added to the cells, in the presence of Krebs-Ringer.
Fluorescence intensity changes were recorded and
used to calculate the Rnorm, which represents
changes in [Ca2]i. Changes in the Rnorm in GEnC
treated with VEGF-A were compared to effects of
VEGF-C. A: An example of the effect of VEGF-A
on GEnC, showing an increase in Rnorm. B: An
example of the effect of VEGF-C on GEnC, show-
ing an increase in Rnorm. C: An example of VEGF-
C156S, showing no change in Rnorm. D–F: Data
expressed as mean SE of the ratio of treatment/
baseline Rnorm for VEGF-A, VEGF-C, and VEGF-
C156S, respectively, compared to vehicle. The
Rnorm was increased, corresponding to an increase
in [Ca2]i, in GEnC treated with both 1 nmol/L
VEGF-A and 10 nmol/L VEGF-C (P 0.05 in each
case), but not 10 nmol/L VEGF-C156S. Composite
data (D–F) are derived from 5, 12, and 7 experi-
ments, respectively.
Figure 6. The effects of VEGF-A and VEGF-C on
the rate of calcium flux (dRnorm/dt) and the time
taken to reach dRnorm/dt. A: An example dem-
onstrating the comparison between Rnorm and
dRnorm/dt in response to VEGF-A. B: An exam-
ple demonstrating the comparison between
Rnorm and dRnorm/dt in response to VEGF-C. C:
Data expressed as mean  SE of the peak
dRnorm/dt for VEGF-A, VEGF-C. D: Data ex-
pressed as mean  SE time to peak dRnorm/dt
for VEGF-A and VEGF-C. VEGF-A-induced peak
Ca2 flux: 122.35  13.02 seconds; VEGF-C:
415.65  118.4 seconds, P  0.05. Composite
data (C and D) are derived from 5 and 12 ex-
periments, respectively.
VEGF-C and Glomerular Endothelial Cells 943
AJP October 2008, Vol. 173, No. 4
may be switched on in tumor neovasculature where it
appears to be involved in promoting integrity of the en-
dothelial lining.32 This action may be important in GEnC,
which, like tumor vascular endothelial cells, are exposed
to high concentrations of VEGF-A (derived from podo-
cytes in the glomerulus). Confocal microscopy, Western
blotting, and immunoprecipitation studies confirmed the
continued expression of VEGFR-3 by cultured GEnC, in
addition to VEGFR-1 and VEGFR-2 as we have previously
shown.24
Effects of VEGF-C on GEnC Monolayer Barrier
Properties
VEGF-C caused an increase in TEER of GEnC monolay-
ers. TEER is a measure of ion flux and is inversely related
to the fractional area of pathways open to water and small
molecules across a cell monolayer. An increase in resis-
tance suggests a reduction in such pathways. The ob-
served maximal increase of 6.8 is similar to the re-
sponse to ang1 (5.7), one of few other mediators known
to reduce endothelial permeability.24 VEGF-C caused a
corresponding reduction in FITC-BSA passage; the
32.8% reduction in FITC-BSA passage is similar to the
45.2% reduction induced by ang1.24 VEGF-C thus has
comparable effects in these respects to ang1 but oppo-
site effects to those of VEGF-A. As we have shown pre-
viously VEGF-A reduces GEnC TEER (confirmed here)
and increases passage of labeled albumin.24
This interesting observation raises the question of why
two members of the VEGF family should have opposite
effects on GEnC barrier properties. These in vitro results
also contrast with in vivo effects of VEGF-C on frog mes-
enteric capillaries where VEGF-C increases hydraulic
conductivity, at least in a proportion of vessels,33 and
increases leakage of Evans blue dye in the Miles assay.7
Explanations for these apparent contradictions may lie in
the important differences between VEGF-A and VEGF-C
in their receptor-binding specificities and in the expres-
sion of VEGFR-3 in GEnC but not in systemic vessels.
Effects of VEGF-C on [Ca2]i
In view of opposite effects of VEGF-A and VEGF-C on
barrier properties of GEnC, we went on to compare the
[Ca2]i responses to VEGF-C. VEGF-A is known to cause
an increase in [Ca2]i in other endothelial cell types (both
in vitro in HUVEC,30,34 and in vivo in frog mesenteric
vessels35). After VEGF-A or other stimuli, an increase in
[Ca2]i is usually associated with an increase in perme-
ability. In contrast to the barrier property assays, VEGF-C
here behaved similarly to VEGF-A, causing an increase in
[Ca2]i. Another group has shown that VEGF-D increases
[Ca2]i in HUVEC,
30 and our novel finding of an increase
in [Ca2]i in response to VEGF-C is hence consistent with
Figure 7. The effects of VEGF-A and VEGF-C on phosphorylation of
VEGFR-2 in cultured GEnC. GEnC were serum-starved, then treated with 1
nmol/L VEGF-A, 10 nmol/L VEGF-C, or vehicle for varying lengths of time
before cells were lysed and protein immunoprecipitated with VEGFR-2
antibodies. Immunoprecipitated protein plus lysate and total protein was run
on a SDS-PAGE and Western blotting was performed using either a phos-
photyrosine (PY) antibody or an antibody to VEGFR-2 to demonstrate total
protein. A: VEGF-A at 2 minutes induced a much more intense phosphoty-
rosine band corresponding to VEGFR-2 than VEGF-C at 10 minutes. B:
VEGF-C induced maximal VEGFR-2 phosphorylation at 30 minutes, which
was reduced by 90 minutes. Numbers indicate position of molecular weight
markers of corresponding size. Arrows indicate position of bands corre-
sponding to VEGFR-2. Blots shown are representative of five separate
experiments.
Figure 8. The effect of VEGF-C and VEGF-C156S on phosphorylation of
VEGFR-3 in cultured GEnC (A) and LEC used here as a positive control (B).
A: GEnC were serum-starved, then treated with 10 nmol/L VEGF-C, 10
nmol/L VEGF-C156S, or vehicle for 5 minutes before cells were lysed and
protein immunoprecipitated with VEGFR-3 (9D9) antibodies. Immunopre-
cipitated protein was run on a SDS-PAGE and Western blotting was per-
formed using antibodies to either phosphotyrosine (PY) or to VEGFR-3
(AF349) to demonstrate total protein. The positions of the 130-, 170-, and
195-kDa VEGFR-3 bands are indicated in the total protein blot. Neither
VEGF-C nor VEGF-C156S induced VEGFR-3 phosphorylation. Blots shown
are representative of three separate experiments. B: LEC were treated as for
GEnC. Phosphorylation of VEGFR-3 was not detected in the control lane, but
was up-regulated by both VEGF-C and the VEGF-C156S mutant as expected.
Phosphorylation is most clearly seen in the 130-kDa band. These results
confirm the activity of VEGF-C and VEGF-C156S and the ability of this assay
to detect VEGFR-3 phosphorylation. Arrows indicate the position of bands
corresponding to VEGFR-3. These results confirm the activity of VEGF-C and
VEGF-C156S and the ability of this assay to detect VEGFR-3 phosphorylation.
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effects of other VEGF family members. However, the
finding is surprising in the context of evidence of reduced
permeability.
An explanation may lie in accumulating evidence
showing that microvascular endothelial cells are relatively
resistance to permeability increases as a consequence
of raised [Ca2]i because of differences from macrovas-
cular endothelial cells in regulation of store-operated cal-
cium entry.36 Furthermore the increase in [Ca2]i in re-
sponse to VEGF-C was smaller than that to VEGF-A,
suggesting that there may be a threshold level of [Ca2]i
required to increase permeability, as previously shown
for mesenteric microvessels.37 In view of recent evidence
showing that in vivo permeability changes depend also on
the rate of change of [Ca2]i,
38 we also determined the
peak rate of change of [Ca2]i. Although we could not
demonstrate a difference in this measure per se, the
timing of the peak rate of change of [Ca2]i was much
later in cells treated with VEGF-C confirming a delayed
response profile, which may have implications for down-
stream signaling events.
Lack of Effect of VEGF-C156S and Receptor
Phosphorylation Studies
To further investigate this differential effect of VEGF-A
and VEGF-C, we sought to determine through which re-
ceptor VEGF-C was exerting its effects. VEGF-C156S,
which binds to VEGFR-3 but not VEGFR-2, had no effect
on GEnC TEER or on [Ca2]i. Differences in VEGFR-3
binding affinity and hence activation between wild-type
VEGF-C and VEGF-C156S suggest a possible explana-
tion for the lack of effect of VEGF-C156S.5 However, at
concentrations used, it would be expected that VEGFR-3
would be saturated and in lymphangiogenesis assays,
VEGF-C and VEGF-C156S can be shown to be equipo-
tent.14 Hence it is more likely that the absence of
VEGFR-2 binding is the reason for the absence of an
effect of VEGF-C156S.39
To determine whether wild-type VEGF-C was acting via
VEGFR-2 or VEGFR-3, we studied receptor phosphoryla-
tion. VEGF-C phosphorylated VEGFR-2 to a lesser extent
and with a delayed effect when compared to VEGF-A, as
seen with the effect on [Ca2]i and as has been shown for
VEGF-D.30 Neither VEGF-C, nor the VEGFR-3-specific
mutant VEGF-C156S, could be shown to phosphorylate
VEGFR-3 in GEnC. Taken together with the absence of
effects of VEGF-C156S on TEER or [Ca2]i, and the phos-
phorylation of VEGFR-2 in response to VEGF-C, these
results suggest the relative unimportance of VEGFR-3 in
the effects of VEGF-C on GEnC barrier properties and
[Ca2]i but do not exclude a role for it. We should note
that our results are inconsistent with previous reports
showing phosphorylation of VEGFR-3 by VEGF-C in LEC,
as repeated here, and in blood vascular endothelial
cells.40 However, LEC natively express high levels of
VEGFR-3 and where this effect has been shown in blood
vascular endothelial cells, it has been in cells overex-
pressing VEGFR-3, rather than in primary culture cells
constitutively expressing both VEGFR-2 and VEGFR-3. It
may be that either VEGFR-3 behaves differently in re-
sponse to VEGF-C when artificially overexpressed or
more likely that overexpression allows detection of a low
level of phosphorylation that cannot be detected in GEnC
expressing normal VEGFR-3 levels. Similarly VEGF-C does
not phosphorylate VEGFR-3 in cultured podocytes, which
also constitutively express the receptor.28
Analysis of Downstream Effector Molecules
The intracellular pathways by which VEGF-A acts to in-
crease endothelial cell permeability are complex and
incompletely understood.3 However, effects on intercel-
lular junctions and the actin cytoskeleton have been iden-
tified as important in transducing permeability effects.
VE-cadherin is an endothelial cell-specific adhesion mol-
ecule with important roles in adherens junctions.
VEGFR-2 phosphorylation leads to phosphorylation of
VE-cadherin, disassembly of intercellular junctions, and
Figure 9. The effect of VEGF-A and VEGF-C on phosphorylation of VE-
cadherin (A) and MLC-2 (B) by Western blotting. GEnC were serum-starved
for 4 hours, then treated with 1 nmol/L VEGF-A or 10 nmol/L VEGF-C for 30
minutes (VE-cadherin) or 10 minutes (MLC-2). Membranes were probed for
phospho-VE-cadherin and phospho-MLC-2, respectively, then stripped and
reprobed for total protein. Blots are representative of three and five separate
experiments, respectively. A: Densitometry shows that VEGF-A caused a
2.2  0.12-fold increase in VE-cadherin phosphorylation, whereas VEGF-C
had a minimal increase (1.2 0.2). Overall P 0.016 by analysis of variance,
post hoc (Bonferroni) vehicle versus VEGF-A: P  0.023; vehicle versus
VEGF-C: ns. B: Densitometry shows a trend toward up-regulation of MLC-2
phosphorylation in response to VEGF-A (1.8  0.3-fold increase) whereas
VEGF-C had a minimal effect (1.2  0.2). Overall P  0.10 by analysis of
variance.
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hence to an increase in permeability.41 VEGFR-2 phos-
phorylation also leads to MLC-2 phosphorylation includ-
ing via raised intracellular calcium but also through other
signaling intermediaries. MLC-2 phosphorylation leads to
actin-myosin cross-bridging and a cytoskeletal contrac-
tive force causing endothelial cell retraction and again an
increase in permeability.42
Hence we studied VE-cadherin and MLC-2 as exam-
ples of effector molecules implicated in VEGF-A-induced
increases in endothelial permeability. As anticipated from
work in other types of endothelial cell, VEGF-A increased
phosphorylation of both VE-cadherin and MLC-2 (trend
only) in GEnC. More interestingly, however, VEGF-C did
not lead to phosphorylation of either of these proteins.
These observations confirm that in these studies
VEGFR-2 phosphorylation and raised [Ca2]i in response
to VEGF-C did not lead to the usual downstream effector
activation and hence provide a mechanistic explanation
of why VEGF-C did not increase GEnC permeability. Ei-
ther the time course and degree of VEGFR-2 phosphor-
ylation or the rise in [Ca2]i are insufficient to trigger
activation of these downstream effectors or the pathways
are subject to extrinsic modifiers, for example Rho family
GTPases.
Summary of Experimental Results
We have confirmed the expression of VEGFR-3 on GEnC
both in vivo and in vitro and we have described for the first
time the effects of VEGF-C on barrier properties and
[Ca2]i in cultured endothelial cells of any origin. VEGF-C
increases TEER and reduces protein passage across
GEnC monolayers whilst also increasing [Ca2]i. It does
not phosphorylate the downstream effectors of VEGF-A,
VE-cadherin, and MLC-2. Hence in these cells the rise in
[Ca2]i is dissociated from its usual effect of increasing
permeability.
Implications and Conclusions
What are the possible explanations for the differential
effects of VEGF-A and VEGF-C on GEnC barrier proper-
ties (despite both activating VEGFR-2) and what might be
the role of VEGFR-3 in GEnC in the absence of demon-
strable phosphorylation? Firstly, receptor tyrosine ki-
nases, including VEGFRs, require ligand-induced dimer-
ization and trans-phosphorylation for activation. VEGF-C
can induce both VEGFR-3 homodimerization and het-
erodimerization with VEGFR-2. Different patterns of phos-
phorylation of tyrosyl phosphorylation sites within the in-
tracytoplasmic C-terminal portion of VEGFRs may result
from hetero- or homodimer formation.39 Downstream ef-
fects of such differences are yet to be elucidated but this
provides a potential mechanism whereby VEGF-C-in-
duced VEGFR-2/3 heterodimerization could modulate
downstream events in the absence of VEGFR-3 phos-
phorylation. The co-expression of VEGFR-3 and VEGFR-2
in certain blood vessels also suggests that heterodimer-
ization may occur in vivo and these differences in phos-
phorylation may be important.
Secondly, binding of different ligands to the same
VEGFR can induce different phosphorylation patterns
and downstream events30,43 suggesting another poten-
tial explanation for the differences in both VEGFR-2 phos-
phorylation profiles and in observed effects on barrier
properties and [Ca2]i. The third possible explanation
lies in recent evidence that permeability-inducing effects
of VEGFs depend on VEGFR-1 binding.44 Hence be-
cause VEGF-C does not activate VEGFR-1 it does not
increase permeability but does induce VEGFR-2-depen-
dent events including raised intracellular calcium.44
Our results support the hypothesis that VEGF-C pro-
duced by podocytes has effects on the function of GEnC.
VEGF-C is thus added to the list of mediators, which
already includes VEGF-A,24 VEGF-A165b,
45 and ang1,24
through which the podocyte may direct the GEnC phe-
notype. Apart from VEGF-A, this list includes mediators
that tend to block or antagonize some of the effects of
VEGF-A. As such they may help to explain why GEnC can
be exposed to high levels of VEGF-A and yet contribute
to the permeability barrier and resist the pro-angiogenic
stimulus, at least in the normal state. This combination of
growth factors may induce fenestrations while retaining
GEnC in a quiescent state. The concurrence of VEGFR-3
with VEGFR-2 expression in fenestrated endothelia in
other organs further points to the importance of VEGFR-3
in determining the phenotype of fenestrated endothelia.
Other observations support this idea, suggesting that
VEGFR-3 modulates signaling via VEGFR-2 to stabilize the
endothelium32,46 and regulates embryonic vasculogen-
esis.47 In a recent study in adult animals, Kamba and col-
leagues19 showed that some capillaries in various organs
regress on systematic VEGF-A blockade. Those vessels
that regressed (ie, were VEGF-A-dependent) not only had
relatively high levels of VEGFR-2, but also expressed
VEGFR-3, providing further evidence for the importance of
VEGFR-3 in modulating VEGFR-2 responses.
The data described here add to the increasing com-
plexity of signaling pathways that may maintain the
unique phenotypes of glomerular cells that in turn are
essential for their filtration function. Alterations in levels of
expression of mediators involved in such pathways have
been identified in various glomerular diseases and in
recovery from them.21 In some situations, recovery from
glomerular injury can be shown to be dependent on
restoration of the normal glomerular endothelium.2 Exog-
enous administration of VEGF-A has been shown to has-
ten recovery in experimental glomerulonephritis48 and
VEGF-A is already in use in clinical trials in peripheral and
cardiovascular disease.49 Further elucidation of these
glomerular pathways will inform development of thera-
peutic approaches involving the manipulation of various
mediators, tailored according to the particular patho-
physiological process.
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